Investopedia: The Week Ahead In Healthcare

Healthcare has settled back into its normal late summer routine, with relatively little in the way of new product introductions or other market-moving data. That's not to say that the space is entirely quiet, though, as business continues to go on.

Novo Continues to Drive One of the Greatest Growth Stories in Healthcare
Very few healthcare stocks are as expensive as Novo Nordisk (NYSE:NVO), but few companies deserve that sort of premium either. There aren't too many companies with multiple billions of dollars in revenue that are growing more than 20%, but Novo is managing to do so largely on the strength of its diabetes franchise. Novo Nordisk stands tall alongside Lilly (NYSE:LLY) and Sanofi (NYSE:SNY) in the insulin space, while its Victoza remains a leading pharmaceutical option for Type 2 diabetes.

Please continue here:
http://stocks.investopedia.com/stock-analysis/2012/The-Week-Ahead-In-Healthcare-PFE-JNJ-TARO-NVO0813.aspx